The NCCN Guidelines for Colon Cancer, Version 1.2017, focus on the use of systemic therapy in metastatic disease. The guidelines consider factors such as treatment history, disease extent, treatment goals, regimen efficacy and toxicity, KRAS/NRAS mutational status, and patient comorbidities and preferences. The location of the primary tumor, BRAF mutation status, and tumor microsatellite stability are also considered in treatment decisions. The guidelines are categorized into evidence levels, with most recommendations being Category 2A. Clinical trials are encouraged for cancer patients. The guidelines cover diagnosis, staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. They emphasize the TNM staging system and recommend a continuum of care for advanced or metastatic disease. The guidelines suggest various chemotherapy regimens, including FOLFOX, FOLFIRI, CapeOx, and others, with or without targeted agents. The choice of therapy depends on the patient's goals, prior treatment, tumor mutational profile, and drug toxicity. The guidelines also discuss the use of bevacizumab, cetuximab, and panitumumab, noting their effectiveness in certain patient populations and the importance of KRAS/NRAS and BRAF mutation testing. The guidelines recommend against using EGFR inhibitors in patients with right-sided primary tumors and emphasize the importance of molecular testing to guide treatment decisions. The guidelines also address the use of maintenance therapy and the role of bevacizumab in first-line treatment, highlighting its benefits and risks. The guidelines are intended to provide a comprehensive approach to the management of colon cancer, with a focus on individualized treatment based on the patient's specific circumstances.The NCCN Guidelines for Colon Cancer, Version 1.2017, focus on the use of systemic therapy in metastatic disease. The guidelines consider factors such as treatment history, disease extent, treatment goals, regimen efficacy and toxicity, KRAS/NRAS mutational status, and patient comorbidities and preferences. The location of the primary tumor, BRAF mutation status, and tumor microsatellite stability are also considered in treatment decisions. The guidelines are categorized into evidence levels, with most recommendations being Category 2A. Clinical trials are encouraged for cancer patients. The guidelines cover diagnosis, staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. They emphasize the TNM staging system and recommend a continuum of care for advanced or metastatic disease. The guidelines suggest various chemotherapy regimens, including FOLFOX, FOLFIRI, CapeOx, and others, with or without targeted agents. The choice of therapy depends on the patient's goals, prior treatment, tumor mutational profile, and drug toxicity. The guidelines also discuss the use of bevacizumab, cetuximab, and panitumumab, noting their effectiveness in certain patient populations and the importance of KRAS/NRAS and BRAF mutation testing. The guidelines recommend against using EGFR inhibitors in patients with right-sided primary tumors and emphasize the importance of molecular testing to guide treatment decisions. The guidelines also address the use of maintenance therapy and the role of bevacizumab in first-line treatment, highlighting its benefits and risks. The guidelines are intended to provide a comprehensive approach to the management of colon cancer, with a focus on individualized treatment based on the patient's specific circumstances.